文献速递淋巴瘤

多柔比星暴露与青少年及成人霍奇金淋巴瘤幸存者乳腺癌风险

Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
PubMed 文献 · J Clin Oncol · 2024-02-15

该队列纳入1975至2008年间荷兰20家医院15-50岁治疗的1,964例女性5年霍奇金淋巴瘤幸存者,中位随访21.6年,252例发生浸润性乳腺癌或导管原位癌。多柔比星累积剂量>200 mg/m2者乳腺癌风险为未用多柔比星者的1.5倍(95%CI 1.08-2.1),每增加100 mg/m2风险增加1.18倍(95%CI 1.05-1.32,Ptrend=.004)。

要点

  • 多柔比星累积剂量>200 mg/m2者乳腺癌风险为未用者的1.5倍(95%CI 1.08-2.1)。
  • 每增加100 mg/m2多柔比星,乳腺癌风险增加1.18倍(95%CI 1.05-1.32,Ptrend=.004)。
  • 30年乳腺癌累积发生率为20.8%(95%CI 18.2-23.4)。

核心结论

  • 本研究表明,在青少年和成人霍奇金淋巴瘤幸存者中,多柔比星治疗与乳腺癌风险增加相关。
  • 结果对霍奇金淋巴瘤幸存者的乳腺癌监测指南和新诊断患者的治疗策略有启示。

研究设计与样本

  • 在荷兰20家医院1975至2008年间治疗的1,964例15-50岁女性5年霍奇金淋巴瘤幸存者队列中评估乳腺癌风险。
  • 计算标准化发病比、绝对超额风险和累积发病率,采用多变量Cox回归分析多柔比星暴露。

主要发现

  • 中位随访21.6年(IQR 15.8-27.1年)后,252例女性发生浸润性乳腺癌或导管原位癌。
  • 30年累积发病率为20.8%(95%CI 18.2-23.4)。
  • 多柔比星累积剂量>200 mg/m2者较未用多柔比星者乳腺癌风险增加1.5倍(95%CI 1.08-2.1)。
  • 每增加100 mg/m2多柔比星,乳腺癌风险增加1.18倍(95%CI 1.05-1.32,Ptrend=.004)。
  • 多柔比星(是 vs 否)相关风险增加未受首次治疗年龄或胸部放疗修饰:首次治疗年龄<21岁HR 1.5(95%CI 0.9-2.6),≥21岁HR 1.3(95%CI 0.9-1.9);无斗篷/腋窝野放疗HR 1.9(95%CI 1.06-3.3),有斗篷/腋窝野放疗HR 1.2(95%CI 0.8-1.8)。

临床怎么用

  • 原文未据此给出推荐,结论指出结果对霍奇金淋巴瘤幸存者的乳腺癌监测指南和新诊断患者的治疗策略有启示。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Female Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) at a young age have a strongly increased risk of breast cancer (BC). Studies in childhood cancer survivors have shown that doxorubicin exposure may also increase BC risk. Although doxorubicin is the cornerstone of HL chemotherapy, the association between doxorubicin and BC risk has not been examined in HL survivors treated at adult ages. METHODS: We assessed BC risk in a cohort of 1,964 female 5-year HL survivors, treated at age 15-50 years in 20 Dutch hospitals between 1975 and 2008. We calculated standardized incidence ratios, absolute excess risks, and cumulative incidences. Doxorubicin exposure was analyzed using multivariable Cox regression analyses. RESULTS: After a median follow-up of 21.6 years (IQR, 15.8-27.1 years), 252 women had developed invasive BC or ductal carcinoma in situ. The 30-year cumulative incidence was 20.8% (95% CI, 18.2 to 23.4). Survivors treated with a cumulative doxorubicin dose of >200 mg/m2 had a 1.5-fold increased BC risk (95% CI, 1.08 to 2.1), compared with survivors not treated with doxorubicin. BC risk increased 1.18-fold (95% CI, 1.05 to 1.32) per additional 100 mg/m2 doxorubicin (Ptrend = .004). The risk increase associated with doxorubicin (yes v no) was not modified by age at first treatment (hazard ratio [HR]age <21 years, 1.5 [95% CI, 0.9 to 2.6]; HRage ≥21 years, 1.3 [95% CI, 0.9 to 1.9) or chest RT (HRwithout mantle/axillary field RT, 1.9 [95% CI, 1.06 to 3.3]; HRwith mantle/axillary field RT, 1.2 [95% CI, 0.8 to 1.8]). CONCLUSION: This study shows that treatment with doxorubicin is associated with increased BC risk in both adolescent and adult HL survivors. Our results have implications for BC surveillance guidelines for HL survivors and treatment strategies for patients with newly diagnosed HL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Neppelenbroek SIM, Geurts YM, Aleman BMP, et al. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma. J Clin Oncol. 2024. PMID: 38359378. doi:10.1200/JCO.23.01386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。